The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Numinus files a patent application for a "process" that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.
Novamind's new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.
Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.
Cybin's latest R&D initiative (CYB004) is a proprietary molecule targeting anxiety disorders.
Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now